Volume 82 - 2019 - Fasc.2 - Case reports
Olmesartan-induced enteropathy treated with budesonide
Olmesartan, an angiotensin receptor blocker, is a widely spread antihypertensive drug. Seronegative villous atrophy of the small intestine due to olmesartan use was first described in 2012. We present a new case of olmesartan-induced enteropathy and compare it to recent literature. This case might suggest a use of budesonide for treatment. (Acta gastroenterol. belg., 2019, 82, 319-321).
Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review
Colorectal cancer is one of the most frequently diagnosed malignancies worldwide. One of the most important developments in the management of metastatic colorectal cancer is targeted therapy. Bevacizumab, a monoclonal antibody inhibiting VEGF induced angiogenesis, has been accepted as safe and efficient in the treatment of metastatic colorectal cancer for more than a decade. Addition of bevacizumab to fluorouracil-based chemotherapy is also associated with severe adverse events. We present a case of bevacizumab-induced bowel ischaemia associated with gastro- intestinal haemorrhage. (Acta gastroenterol. belg., 2019, 82, 322- 325).
Cheilitis granulomatosa and Crohn's disease : a case report
Cheilitis granulomatosa (CG) is a rare, persistent, non-tender swelling of one or both lips caused by a non caseating, granulomatous inflammation, first described by Miescher in 1945 (1). CG can be a manifestation of a systemic granulomatous condition such as Crohn's disease or Sarcoidosis, it can be idiopathic or it can be part of the Melkersson-Rosenthal syndrome which is a triad of recurrent orofacial swelling, fissured tongue, and intermittent facial palsy.
Colorectal cribriform comedo-type adenocarcinoma: a distinct subtype with poor prognosis?
Colorectal cancer is one of the most commonly diagnosed cancers in the world. It is a heterogeneous disease with several histologic subtypes, and some of them are associated with adverse prognostic factors. Cribriform comedo-type adenocarcinoma (CCA) has been included as a colorectal adenocarcinoma subtype in the last World Health Organization (WHO) classification of gastrointestinal system tumors. Some authors have linked this subtype to an adverse prognosis, but to the best of our knowledge there is only one previous report assessing its histologic and prognostic features. We herein review a series of CCA of the colon, emphasizing its clinical and morphological features. (Acta gastroenterol. belg., 2019, 82, 329-332).
